AliveCor Kardia 12L and KardiaPro

AliveCor, Inc. is a privately held company headquartered in Mountain View, California, that provides FDA-cleared personal ECG technology and medical-grade AI. Its page cites more than 200 clinical publications and 3 million lifetime users in over 40 countries.

The Kardia 12L is a handheld, AI-powered 12-lead ECG system with a single cable that detects 35 cardiac determinations, 14 arrhythmias and 21 morphologies. KardiaPro, KardiaStation and KardiaCare Plus connect device data to clinician workflows, and API and SDK solutions let third parties integrate. The Kardia 12L launched in India in July 2025 with CDSCO approval and in Europe in April 2026.

• Handheld 12-lead ECG: Kardia 12L with a single-cable design and battery operation.
• AI interpretation: 35 cardiac determinations including heart attack and common types of ischemia.
• Personal ECG: KardiaMobile 6L for arrhythmia detection by patients.
• Clinician software: KardiaPro, KardiaStation and KardiaCare Plus.
• API and SDK: data integration solutions for third-party platforms.
• Reimbursed programs: KardiaACCESS and KardiaComplete for payers and employers.

District and community clinics adding 12-lead ECG screening without a fixed ECG cart. Corporate health check programs screening cardiac risk with remote cardiologist reading. Cardiology practices monitoring patients with arrhythmia between visits.

A 12-lead ECG that weighs about 135 grams and fits in a lab coat pocket suits clinics without a full ECG cart. A reduced leadset means patients do not need to fully undress. Minimal training is required compared with standard 12-lead machines. Remote data sharing connects patients with cardiologists.

Portable and AI-assisted ECG is expanding in Asia, where AliveCor launched the Kardia 12L in India in 2025. Vietnam and Southeast Asia have limited ECG access in district clinics and growing demand for point-of-care cardiac screening and remote reading by cardiologists.

Headquartered in Mountain View, California. FDA clearance of new cardiac determinations for the Kardia 12L brought the total to 39 in January 2026, and CMS reimbursement approval followed in January 2025. Partners listed include WELL Health (Canada) and Hannover Medical School. Founding year not stated.